Iopamiro (Iopamidol)

Iopamidol contains iodine atoms that strongly absorb X‑rays. When injected, it distributes in the vascular and extracellular spaces, creating osmotic gradients that increase X‑ray attenuation of the targeted area. This contrast enhancement makes anatomical structures appear brighter on radiographic images, facilitating accurate diagnosis.

The dose of Iopamiro is determined by the prescribing physician based on the specific imaging study, patient size, and renal function. Dosage is calculated to achieve adequate contrast while minimizing risk, and is administered by a qualified healthcare professional under controlled conditions.

The safety of Iopamiro during pregnancy and lactation has not been definitively established. It should be used only if the potential diagnostic benefit outweighs any possible risk to the fetus or infant, and the decision should be made by the treating physician in consultation with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Iopamiro. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Iopamiro is a non‑ionic, low‑osmolality iodinated contrast medium, offering a lower incidence of adverse reactions compared with older high‑osmolality ionic agents. Compared with other non‑ionic agents, it provides similar image quality and safety profiles, but specific choice may depend on formulation, concentration, and institutional preference.

Iopamiro should be stored at controlled room temperature, below 25 °C, in its original sealed container. Protect the solution from direct sunlight, moisture, and freezing. Inspect the vial for particulate matter before use, and discard any product that appears discolored or contains precipitates.

Iopamiro is supplied as a sterile solution for injection and is administered intravenously, intra‑arterially, or intrathecally by a trained healthcare professional. The injection is typically performed using a power injector or manual bolus, following aseptic technique and according to the imaging protocol prescribed for the specific diagnostic procedure.

The most serious risks associated with Iopamiro include severe allergic reactions such as anaphylaxis, acute kidney injury especially in patients with pre‑existing renal impairment, and cardiovascular collapse. Immediate monitoring of vital signs during and after administration is essential, and emergency measures should be readily available to manage these potential events.

Iopamiro should be avoided in patients with a known hypersensitivity to iodinated contrast media, a history of severe iodine allergy, or uncontrolled thyroid disease. Caution is also advised for individuals with compromised renal function, heart failure, or those receiving nephrotoxic medications, as the risk of adverse reactions may be heightened.